Veradermics, Incorporated (MANE) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), Veradermics, Incorporated had return on equity of -72.1% (up from -82.1%), debt-to-equity of 0.00, a current ratio of 16.66 (up from 11.77) and return on assets of -43.4% (up from -45.8%). A current ratio of 16.66 means current assets exceed current liabilities.

Veradermics, Incorporated Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Income Statement Balance Sheet Cash Flow Ratios

Scroll to see more

Breakdown	FY 2025	FY 2024	FY 2023
Period ending	Dec 2025	Dec 2024	Dec 2023
Valuation Ratios
Enterprise Value Ratios
Profitability & Returns
Return on Equity (ROE)	-72.06%	-82.08%	-
Return on Assets (ROA)	-43.44%	-45.79%	-
Return on Capital Employed (ROCE)	-50.40%	-52.70%	-119.40%
Leverage & Solvency Ratios
Debt/Equity	0.00	-	0.06
Liquidity Ratios
Current Ratio	16.66	11.77	5.75
Quick Ratio	15.64	11.54	5.34
Efficiency Ratios
Yield & Distribution Ratios
Buyback Yield	-1.09%	-	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Veradermics, Incorporated Financial Ratios

What is Veradermics, Incorporated's return on equity?

Veradermics, Incorporated's return on equity (ROE) was -72.1% for fiscal 2025 (period ended Dec 31, 2025). It was -82.1% a year earlier.

What is Veradermics, Incorporated's debt-to-equity ratio?

Veradermics, Incorporated's debt-to-equity ratio was 0.00 for fiscal 2025 (period ended Dec 31, 2025).

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition